Thyroid Nodules and Thyroid Cancer
Thyroid nodules are among the most common findings in endocrine medicine, detectable by ultrasound in roughly 50–60% of the general adult population according to the American Thyroid Association (ATA). The critical clinical question with any nodule is distinguishing benign growths from the small fraction that represent thyroid cancer. This page covers the classification of nodule types, the diagnostic pathway from imaging through biopsy, how malignancy is staged and treated, and the thresholds that drive clinical decisions.
Definition and Scope
A thyroid nodule is a discrete lesion within the thyroid gland that is radiologically distinct from surrounding parenchyma. Nodules range from microscopic incidental findings to masses exceeding 4 centimeters. The ATA 2015 Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer remain the primary reference framework governing evaluation and management in the United States.
Thyroid cancer accounts for approximately 2% of all new cancer diagnoses in the US annually, with the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program estimating roughly 43,720 new cases in 2023. Despite that volume, thyroid cancer carries one of the highest 5-year relative survival rates of any malignancy — approximately 98% for localized differentiated disease per SEER data — largely because most cases are detected early and respond well to established treatment.
Nodule evaluation intersects the broader regulatory context for endocrinology, including FDA oversight of diagnostic ultrasound equipment, pathology laboratory standards under CLIA (Clinical Laboratory Improvement Amendments, 42 CFR Part 493), and CMS reimbursement policies governing thyroid ultrasound and fine-needle aspiration (FNA) biopsy codes.
How It Works
Diagnostic Pathway
Evaluation proceeds through a structured sequence:
- Serum TSH measurement — Suppressed TSH suggests a hyperfunctioning ("hot") nodule, which has near-zero malignancy risk. Elevated or normal TSH directs attention toward morphology.
- Thyroid ultrasound — The foundational imaging study. Ultrasound characterizes nodule size, composition (solid, cystic, or mixed), echogenicity, margins, shape, and the presence of calcifications. The ATA risk stratification system grades nodules as high suspicion, intermediate suspicion, low suspicion, very low suspicion, or benign based on sonographic pattern.
- The ACR TIRADS system — The American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) assigns scores from TR1 (benign) to TR5 (highly suspicious) based on five ultrasound feature categories, each carrying a weighted point value. A TR5 designation with a nodule ≥1 cm triggers a recommendation for FNA biopsy.
- Fine-needle aspiration (FNA) biopsy — Ultrasound-guided FNA yields cytologic material categorized under the Bethesda System for Reporting Thyroid Cytopathology, a 6-tier classification ranging from Bethesda I (nondiagnostic) through Bethesda VI (malignant). Bethesda III and IV categories ("atypia of undetermined significance" and "follicular neoplasm") carry intermediate malignancy risks of approximately 10–30% and 25–40% respectively, per ATA estimates.
- Molecular testing — For indeterminate FNA results (Bethesda III/IV), molecular panels such as Afirma Gene Sequencing Classifier or ThyroSeq v3 provide additional risk stratification, though the FDA regulates these as laboratory-developed tests under CLIA authority.
Malignancy Types and Classification Boundaries
Thyroid cancers divide into four principal histologic categories:
| Type | Frequency | Key Features |
|---|---|---|
| Papillary thyroid carcinoma (PTC) | ~85% of cases | Characteristic nuclear grooves; frequently multifocal; excellent prognosis |
| Follicular thyroid carcinoma (FTC) | ~10% | Capsular/vascular invasion distinguishes from adenoma; no FNA diagnosis possible |
| Medullary thyroid carcinoma (MTC) | ~2–3% | Arises from parafollicular C-cells; associated with RET mutation and MEN2 syndromes |
| Anaplastic thyroid carcinoma (ATC) | <2% | Undifferentiated; median survival under 6 months; managed under FDA Breakthrough Therapy designations for targeted agents |
Staging follows the American Joint Committee on Cancer (AJCC) TNM system, 8th Edition, which reclassified the age cutoff for differentiated thyroid cancer from 45 to 55 years, significantly shifting the distribution of Stage I vs. Stage II disease.
Common Scenarios
Incidental nodule on imaging — A nodule discovered on CT, MRI, or PET ordered for unrelated reasons is termed a "thyroid incidentaloma." The ATA recommends against FNA for purely cystic nodules or nodules with ≥2 benign features regardless of size, directing physicians to serial surveillance instead.
Multinodular goiter — When the thyroid contains 3 or more nodules, each must be assessed individually. The nodule with the highest ACR TI-RADS score drives the biopsy decision, not the dominant nodule by size alone.
Elevated calcitonin — Serum calcitonin elevation raises concern for medullary thyroid carcinoma. The European Thyroid Association recommends routine calcitonin screening in all thyroid nodule evaluations, a position not yet universally adopted in ATA guidelines, creating a notable transatlantic divergence in practice.
Post-treatment surveillance — Following thyroidectomy for differentiated thyroid cancer, surveillance relies on serial thyroglobulin (Tg) measurement and neck ultrasound. Undetectable Tg on thyroid hormone replacement with no structural disease on imaging defines biochemical remission under ATA criteria.
Decision Boundaries
The decision to proceed from observation to biopsy to surgery involves size thresholds, ultrasound risk categories, cytology results, and patient-specific factors:
- No FNA indicated for nodules <5 mm regardless of sonographic features (ATA).
- FNA indicated for ≥1 cm nodule with high-suspicion ultrasound pattern (ATA) or TR5 ≥1 cm (ACR TI-RADS).
- Lobectomy vs. total thyroidectomy — For tumors 1–4 cm confined to one lobe with no high-risk features, lobectomy alone is acceptable under the ATA framework, preserving contralateral thyroid function and potentially avoiding lifelong hormone replacement.
- Radioactive iodine (RAI) therapy — Indicated selectively for high-risk differentiated thyroid cancer; not routinely recommended for low-risk Stage I papillary carcinoma following the ATA's 2015 guideline revision.
- Active surveillance for low-risk PTC — Tumors ≤1 cm (papillary microcarcinoma) without extrathyroidal extension or nodal involvement may be monitored without immediate surgery, a protocol validated in long-term Japanese cohort studies published through the Kuma Hospital and Cancer Institute Hospital in Tokyo.
The full landscape of thyroid nodule evaluation, biopsy technique, and surgical options is catalogued across the endocrinologyauthority.com resource index, including dedicated coverage of thyroid ultrasound and biopsy procedures.
References
- American Thyroid Association — Thyroid Nodule Guidelines
- ATA 2015 Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer
- ACR TI-RADS — American College of Radiology Thyroid Imaging Reporting and Data System
- NCI SEER Program — Thyroid Cancer Statistics
- AJCC Cancer Staging Manual, 8th Edition — American Joint Committee on Cancer
- CMS CLIA Regulations — 42 CFR Part 493
- European Thyroid Association — Clinical Guidelines
- National Cancer Institute — Thyroid Cancer Treatment (PDQ)
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)